A retrospective Study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer

다국어 초록 (Multilingual Abstract)

Objective: This study compared the effectiveness, safety, and tolerability of dose-densepaclitaxel and carboplatin plus bevacizumab (ddTC+Bev) with ddTC for advanced ovarian cancer.
Methods: We retrospectively analyzed the clinical records of 134 patients who receivedddTC+Bev or ddTC as first-line chemotherapy for stage III–IV ovarian cancer. Progression-free sur vival as primar y endpoint of this study was compared using the log-rank test. Coxproportional hazards model and propensity score matching (PSM) were used to analyzeprognostic factors, and the frequency of adverse events was examined using the χ2 test.
Results: We categorized 134 patients in the ddTC+Bev (n=57) and ddTC (n=77) groupswho started treatment at four related institutions from November 2013 to December 2017.
No patients used poly (ADP-ribose) polymerase inhibitors as the first line maintenancetherapy. The progression-free sur vival (PFS) of the ddTC+Bev group had a significantlybetter prognosis than that of the ddTC group (hazard ratio [HR]=0.50; 95% confidenceinter val [CI]=0.32–0.79; p<0.003). Multivariate analysis showed that ddTC+Bev regimenwas a prognostic factor. However, intergroup comparison using PSM revealed that thePFS of the ddTC+Bev group had a nonsignificantly better prognosis than that of the ddTCgroup (HR=0.70; 95% CI=0.41–1.20; p=0.189). Few adverse events above G3 were noted forddTC+Bev, which were sufficiently tolerable.
Conclusion: This study could not demonstrate that adding Bev to ddTC improves prognosis.
Further studies with more cases are warranted.